Cambrex Karlskoga AB, a subsidiary of Cambrex Corp., has entered into an agreement to acquire ProSyntest AS, a privately held API R&D company. ProSyntest employs 25 chemists at its Tallinn Technology Park location in Tallinn, Estonia. ProSyntest has expertise in chemical route selection and sample generation, rapid scaleup of products at kilo lab scale, as well as chiral and organometallic chemistries.

The business will be renamed Cambrex Tallinn and Cambrex plans to add more process and analytical chemists at the site and continue early API development work in Tallinn for scale up at Karlskoga and the other Cambrex manufacturing facilities.

“Cambrex Karlskoga has successfully worked with the ProSyntest chemists for the past 15 years, and the acquisition of the business is a natural extension of our long-standing relationship. ProSyntest, located in Eastern Europe, will enable Cambrex to more effectively compete in the high growth early clinical stage pharmaceutical custom development market and provide us with a strong pool of talented chemists to advance numerous proprietary strategic initiatives,” commented Steven Klosk, executive vice president and chief operating officer of Cambrex Corp.